Research Team:

Steven J. Adelman, PhD, FAHA

• CEO, Founder/Board Member Vascular Strategies LLC:
• 20 years in Pharma Discovery
• Former Sr. Director Cardiovascular/Metabolic Diseases Research at Wyeth, advancing 10 compounds to clinical trials in cardiovascular, immune disorders and women’s health. Also key to first drug-eluting stent (Cypher) collaboration with Cordis/J&J which changed the paradigm for Interventional Cardiology.
• Identification, implementation and management of research alliances and development collaborations, in-and out-licensing of technologies
• > 15 patents, numerous publications

George H. Rothblat, PhD, FAHA

• Founder/Board Member Vascular Strategies LLC
• Professor: Children’s Hospital of Philadelphia
• Pioneer in cellular cholesterol metabolism and world expert on mechanisms of cholesterol transport and cellular cholesterol efflux
• 30 years of groundbreaking research, with > 160 peer reviewed manuscripts on mechanisms of atherosclerosis, its mediators, and reversal
• Inventor of key IP in RCT technology.
• Extensive/long-term NIH, AHA, etc. funding

Daniel J. Rader, M.D., FAHA

• Founder/Board Member Vascular Strategies LLC
• Cooper-McClure Associate Professor of Medicine.
• Dir. Preventive Cardiovascular Med., Lipid Clinic Program
• Dir. General Clinical Research Center, Assoc Dir Inst. for Translational Med and Therapeutics, U Penn School of Med
• Recognized expert, with > 22 years experience in preclinical lipoprotein metabolism, clinical trials of HDL, RCT and reversing atherosclerosis
• 274 + manuscripts
• Extensive / long-term NIH, AHA, etc. funding